Trials / Completed
CompletedNCT04916548
Repeated Neurocognitive Measurements in Depressed Patients
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Rebecca Price · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
In this project, we will A) track the functioning of a collection of potential neurobiological targets for depression over time, B) examine how fluctuations in the functioning of those targets relates to real-world functioning, and C) in a subset of the sample, determine how the functioning in those targets is altered by a single dose of ketamine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Intravenous Ketamine | Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min) |
Timeline
- Start date
- 2021-09-16
- Primary completion
- 2023-07-15
- Completion
- 2023-08-15
- First posted
- 2021-06-07
- Last updated
- 2024-08-20
- Results posted
- 2024-08-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04916548. Inclusion in this directory is not an endorsement.